Zacks: Analysts Expect Tabula Rasa HealthCare Inc (TRHC) Will Announce Quarterly Sales of $46.73 Million

Wall Street brokerages expect Tabula Rasa HealthCare Inc (NASDAQ:TRHC) to post $46.73 million in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Tabula Rasa HealthCare’s earnings, with the lowest sales estimate coming in at $46.40 million and the highest estimate coming in at $47.06 million. Tabula Rasa HealthCare reported sales of $29.66 million during the same quarter last year, which indicates a positive year over year growth rate of 57.6%. The firm is expected to report its next earnings results on Monday, August 6th.

According to Zacks, analysts expect that Tabula Rasa HealthCare will report full year sales of $193.29 million for the current fiscal year, with estimates ranging from $191.40 million to $194.97 million. For the next year, analysts expect that the company will post sales of $235.58 million per share, with estimates ranging from $227.40 million to $244.32 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Tabula Rasa HealthCare.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings results on Tuesday, May 8th. The company reported $0.10 earnings per share (EPS) for the quarter. Tabula Rasa HealthCare had a negative net margin of 0.61% and a positive return on equity of 0.38%. The company had revenue of $43.94 million for the quarter, compared to the consensus estimate of $42.60 million. During the same quarter in the prior year, the firm earned $0.08 earnings per share. The company’s revenue for the quarter was up 57.0% compared to the same quarter last year.

TRHC has been the topic of several recent research reports. Oppenheimer upped their price target on shares of Tabula Rasa HealthCare from $35.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, March 13th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $46.00 price target on shares of Tabula Rasa HealthCare in a report on Wednesday, May 9th. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price target (up previously from $46.00) on shares of Tabula Rasa HealthCare in a report on Friday, March 16th. CIBC reaffirmed an “outperform” rating and issued a $47.00 price target (up previously from $35.00) on shares of Tabula Rasa HealthCare in a report on Tuesday, March 13th. Finally, ValuEngine raised shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $46.25.

Shares of Tabula Rasa HealthCare traded down $0.22, hitting $68.41, on Wednesday, according to MarketBeat.com. The company’s stock had a trading volume of 341,638 shares, compared to its average volume of 411,074. Tabula Rasa HealthCare has a 12-month low of $12.63 and a 12-month high of $70.15. The company has a quick ratio of 0.41, a current ratio of 0.45 and a debt-to-equity ratio of 0.01.

In related news, Director Bruce Luehrs sold 32,431 shares of the company’s stock in a transaction that occurred on Thursday, May 17th. The shares were sold at an average price of $49.16, for a total transaction of $1,594,307.96. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Monday, April 9th. The stock was sold at an average price of $38.69, for a total transaction of $309,520.00. The disclosure for this sale can be found here. Insiders have sold 225,842 shares of company stock worth $11,152,820 in the last three months. Insiders own 14.00% of the company’s stock.

Large investors have recently bought and sold shares of the business. Stratos Wealth Partners LTD. purchased a new position in Tabula Rasa HealthCare during the first quarter worth approximately $122,000. MetLife Investment Advisors LLC purchased a new position in Tabula Rasa HealthCare during the fourth quarter worth approximately $139,000. Mason Street Advisors LLC purchased a new position in Tabula Rasa HealthCare during the first quarter worth approximately $139,000. New York State Teachers Retirement System purchased a new position in Tabula Rasa HealthCare during the first quarter worth approximately $182,000. Finally, CT Mason purchased a new position in Tabula Rasa HealthCare during the first quarter worth approximately $183,000. 63.91% of the stock is currently owned by institutional investors.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply